Furst DE - Search Results

1

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.

van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijtens K, Furst DE. van der Heijde D, et al. Among authors: furst de. J Rheumatol. 2012 Jul;39(7):1326-33. doi: 10.3899/jrheum.111171. Epub 2012 May 15. J Rheumatol. 2012. PMID: 22589265 Clinical Trial.

2

Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis.

Alarcón GS, López-Méndez A, Walter J, Boerbooms AM, Russell AS, Furst DE, Rau R, Drosos AA, Bartolucci AA. Alarcón GS, et al. Among authors: furst de. J Rheumatol. 1992 Dec;19(12):1868-73. J Rheumatol. 1992. PMID: 1345138

3

Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis.

Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Furst DE, et al. J Rheumatol. 1990 Dec;17(12):1628-35. J Rheumatol. 1990. PMID: 2084236 Clinical Trial.

4

Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate.

Rooney TW, Furst DE, Koehnke R, Burmeister L. Rooney TW, et al. Among authors: furst de. J Rheumatol. 1993 Aug;20(8):1297-302. J Rheumatol. 1993. PMID: 8230008 Clinical Trial.

5

Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis.

Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Kremer JM, et al. Among authors: furst de. J Rheumatol. 1996 Mar;23(3):459-61. J Rheumatol. 1996. PMID: 8832983 Clinical Trial.

6

Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis.

Furst DE. Furst DE. J Rheumatol Suppl. 1996 Mar;44:86-90. J Rheumatol Suppl. 1996. PMID: 8833062 Review.

7

Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs).

van Gestel AM, Haagsma CJ, Furst DE, van Riel PL. van Gestel AM, et al. Among authors: furst de. Baillieres Clin Rheumatol. 1997 Feb;11(1):65-82. doi: 10.1016/s0950-3579(97)80033-7. Baillieres Clin Rheumatol. 1997. PMID: 9088525 Review.

8

From disease modification to disease control in rheumatoid arthritis.

Furst DE. Furst DE. Clin Exp Rheumatol. 1997 May-Jun;15 Suppl 17:S63-6. Clin Exp Rheumatol. 1997. PMID: 9266134 Review.

9

Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective.

Wallis WJ, Furst DE, Strand V, Keystone E. Wallis WJ, et al. Among authors: furst de. Rheum Dis Clin North Am. 1998 Aug;24(3):537-65. doi: 10.1016/s0889-857x(05)70025-9. Rheum Dis Clin North Am. 1998. PMID: 9710886 Review.

10

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Moreland LW, et al. Among authors: furst de. Ann Intern Med. 1999 Mar 16;130(6):478-86. doi: 10.7326/0003-4819-130-6-199903160-00004. Ann Intern Med. 1999. PMID: 10075615 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

725 results

Search Page